(-)-4-(3-cyanophenyl)-2-trifluoromethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid | 172649-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (-)-4-(3-cyanophenyl)-2-trifluoromethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid
• 英文别名: 4-(3-cyanophenyl)-2-trifluoromethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid；2-(Trifluoromethyl)-4-(3-cyanophenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid；4-(3-cyanophenyl)-5-oxo-2-(trifluoromethyl)-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylic acid
• CAS: 172649-33-1
• 化学式: C₁₈H₁₃F₃N₂O₃
• 分子量: 362.308
• InChiKey: YGDGIAUJXPSGEC-UHFFFAOYSA-N

物化性质

• 沸点：
  496.3±45.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  90.2
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (-)-4-(3-cyanophenyl)-2-trifluoromethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid 以 N-甲基吡咯烷酮 为溶剂， 以79%的产率得到(-)-4-(3-Cyanophenyl)-2-trifluoromethyl-4,6,7,8-tetrahydro-5(1H)-quinolone
  参考文献：
  名称：

  Heterocyclic derivatives

  摘要：

  式I的化合物##STR1##其中R.sup.2，R.sup.3，R.sup.4，R.sup.10和R.sup.11具有规范中给定的任何含义，以及它们的药学上可接受的盐在治疗尿失禁方面是有用的。还披露了制药组合物、制备式I化合物和中间体的方法。

  公开号：

  US05455253A1
• 作为产物：
  描述：

  2-Cyanoethyl 4-(3-cyanophenyl)-2-trifluoromethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate 在 盐酸 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 以95%的产率得到(-)-4-(3-cyanophenyl)-2-trifluoromethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  QUINOLONE DERIVATIVE FOR TREATMENT OF URINARY INCONTINENCE

  摘要：

  公开号：

  EP0755382B1

文献信息

• [EN] QUINOLONE DERIVATIVE FOR TREATMENT OF URINARY INCONTINENCE<br/>[FR] DERIVE DE QUINOLONE UTILISE DANS LE TRAITEMENT DE L'INCONTINENCE URINAIRE
  申请人：ZENECA LIMITED

  公开号：WO1995028388A1

  公开（公告）日：1995-10-26

  (EN) (S)-(-)-4-(3-cyanophenyl)-2-trifluoromethyl-4,6,7,8-tetrahydro-5(1H)quinolone as a potassium channel opener, useful for treating urinary incontinence, and processes for the preparation thereof.(FR) L'invention se rapporte à la (S)-(-)-4-(3-cyanophényl)-2-trifluorométhyl-4,6,7,8-tétrahydro-5(1H)quinolone qui est utilisée comme moyen d'ouverture des canaux potassiques, ainsi que dans le traitement de l'incontinence urinaire, et aux procédés de préparation de ce composé.

  (S)-(-)-4-(3-氰基苯基)-2-三氟甲基-4,6,7,8-四氢-5(1H)喹啉被用作钾通道开放剂，可用于治疗尿失禁，并提供了其制备方法。
• Method
  申请人：Jones Andrew

  公开号：US20050080104A1

  公开（公告）日：2005-04-14

  Process for preparing 3-[(4S)-5-oxo-2-(trifluoromethyl)-1,4,5,6,7,8-hexahydroquinolin-4-yl]benzonitrile, pharmaceutical compositions containing the compound and methods of treatment using the same.

  制备3-[(4S)-5-氧代-2-(三氟甲基)-1,4,5,6,7,8-六氢喹啉-4-基]苯甲腈的过程，含有该化合物的制药组合物以及使用该化合物的治疗方法。
• Alternative esters in the synthesis of ZD0947
  作者：Jonathan D. Moseley

  DOI：10.1016/j.tetlet.2005.03.057

  日期：2005.5

  Alternatives to the original iso-borneol and allyl esters were investigated in the synthesis of ZD0947 (1). Homologous allylic esters were prepared in higher yields and were more readily purified than for the existing route, but offered no further benefits later in the synthesis. However, the PNB-substituted ester series provided crystalline intermediates, higher yields and simplified isolations through-out, and utilised a heterogeneous hydrogenation, thus reducing the residual catalyst levels. (c) 2005 Elsevier Ltd. All rights reserved.
• An asymmetric synthesis of a 4-substituted-1,4-dihydropyridine
  作者：Ian Ashworth、Phillip Hopes、Danny Levin、Ian Patel、Rashida Salloo

  DOI：10.1016/s0040-4039(02)00975-9

  日期：2002.7

  A concise, convergent asymmetric synthesis of the 4-substituted-1,4-dihydropyridine 1 [Ohntnacht, C. J.. Jr.: Trainor, D. A.: Forst, J. M.; Stein, M. M.: Harris. R. J. Patent No. 5,622, 964] has been achieved via a novel asymmetric Michael addition of an optically pure vinylogous amide to all alpha,beta-unsaturated ketone. The overall process is three steps front readily available starting materials and provides an economical manufacturing route to (lie title compound, which was required as a candidate drug for the treatment of urinary incontinence. (C) 2002 Elsevier Science Ltd. All rights reserved.
• METHOD
  申请人：AstraZeneca AB

  公开号：EP1478627A1

  公开（公告）日：2004-11-24